![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Ciprofloxacin, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2010-001 - Rev 03
This Chemical Type CEP, issued on August 13, 2019, remains in force until July 12, 2021, ensuring its reliability within the pharmaceutical industry.
Substance Number 1089 associated with this CEP further emphasizes